Pfizer's 1.25% Rally Amid Tariff Talks, 30% Volume Drop Places It 88th in Market Activity

Pfizer (PFE) saw a 1.25% rise on August 7, 2025, with a trading volume of $1.10 billion, a 30.32% drop from the previous day, ranking 88th in market activity. The stock’s performance was influenced by ongoing discussions between CEO Albert Bourla and the Trump administration regarding tariffs and drug pricing policies. Bourla emphasized a “special relationship” with President Trump, noting productive conversations about potential tariffs on imported drugs, which could reach 250%. However, he highlighted expectations for a “small tariff in the first couple of years” and a possible grace period, signaling cautious optimism about regulatory outcomes.

The administration’s focus on reducing U.S. drug costs through “Most Favored Nation” (MFN) pricing—aligning Medicare and Medicaid rates with the lowest prices in developed nations—also dominated discussions. Bourla stated Pfizer is preparing for price cuts under this policy while navigating uncertainties in tariff implementation, particularly regarding active pharmaceutical ingredients (APIs) sourced internationally. Over 90% of U.S. prescriptions are generic, but branded drugs remain central to Pfizer’s revenue, complicating efforts to mitigate pricing pressures without stifling innovation.

Separately, the Trump administration has urged pharmaceutical companies to raise prices in Europe and other markets to offset lower U.S. rates. European governments, which negotiate drug prices directly, hold significant leverage in these negotiations. While some industry leaders have expressed concerns about reduced R&D funding from U.S. price cuts, Bourla noted ongoing dialogue with administration officials to balance affordability and innovation. The outcome of these discussions will likely shape Pfizer’s strategic adjustments in the coming years.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets. The consistent outperformance highlights the effectiveness of liquidity-driven strategies, with high-volume stocks like Pfizer benefiting from investor behavior and macroeconomic shifts. This approach remains relevant despite varying market conditions, demonstrating reliability for short-term gains.